ArticleScientific reports2026
Discovery of hydroxytriazole as a potential glyoxalase-I inhibitor utilizing computer-aided drug design techniques.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimization of a bis-imine scaffold as a glyoxalase I inhibitor: synthesis, SAR, and docking studies.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glyoxalase system, particularly Glyoxalase-I (Glo-I), plays a crucial role in detoxifying aldehyde metabolites into lactic acid. Inhibiting this enzyme causes the buildup of the poisonous aldehyde, leading to programmed cell death. In this study, molecular modelling techniques were employed, including high-throughput virtual screening (HTVS), followed by filtration procedures such as Lipinski's rule of five and Veber's rules, and finally CDOCKER docking, to prioritize compounds from the commercial Maybridge database. Sixteen compounds were carefully chosen and purchased from the Maybridge database for further experimental evaluation. The integrated computational and experimental workflow successfully culminated in the identification of a novel, potent Glyoxalase-I (Glo-I) inhibitor. One molecule has been discovered to inhibit Glo-I with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.